Soligenix receives fda ind clearance for phase 2 clinical trial of dusquetide in the treatment of aphthous ulcers in behÇet's disease

Pipeline expansion of novel innate defense regulator technology princeton, n.j. , nov. 30, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the u.s. food and drug administration (fda) has cleared the investigational new drug (ind) application for a phase 2a clinical trial entitled, "pilot study of sgx945 (dusquetide) in the treatment of aphthous ulcers in behÇet's disease.
SNGX Ratings Summary
SNGX Quant Ranking